<DOC>
	<DOCNO>NCT02768571</DOCNO>
	<brief_summary>This study , E-COMPASSII phase IV clinical trial design multicenter , randomize , double-blind , placebo-controlled , parallel-group study . This study enroll 80 subacute stroke patient severe motor involvement . Primary objective demonstrate efficacy porcine brain peptide improve motor recovery measure improvement ratio Fugl-Meyer assessment ( ( score FMA 3 week - score FMA baseline ) / score FMA baseline ) patient subacute stroke . Secondary objective evaluate safety profile cerebrolysin test hypothesis subacute stroke patient severe motor involvement randomize administration Cerebrolysin combine rehabilitation 3 week show well outcome global function ( Korean version Modified Barthel Index , K-MBI ) , severity stroke ( National Institute Health Stroke Scale , NIHSS ) , cognitive function ( Korean Version Mini-Mental State Exam , K-MMSE ; Korean version Montreal Cognitive Assessment , K-MoCA ) , upper limb function ( Action Research Arm Test , ARAT ; Box block test , B &amp; B ) neuroplasticity measure ( resting-state functional MRI ( rsfMRI ) , diffusion tensor image ( DTI ) , motor evoke potential ( MEP ) ) 3 month stroke .</brief_summary>
	<brief_title>Effects Cerebrolysin Combined With Rehabilitation Motor Recovery Stroke</brief_title>
	<detailed_description>Randomized double-blinded , placebo-controlled multicenter study two treatment group Number Patients : 80 patient ( n = 40 per group ) 5 study center participate study . Group 1 ( Cerebrolysin ) : cerebrolysin 30 ml 100 ml dilution/day * 21 day rehabilitation Group 2 ( Placebo ) : saline 100 ml/day * 21 day rehabilitation</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Cerebrolysin</mesh_term>
	<criteria>1 . The firstever stroke ( ischemic ) 2 . Confirmed CT MRI 3 . Subacute stage : le 1 week 4 . Severe motor function involvement ( FMA &lt; 50 ) 5 . Age : 19 80 year 6 . Inpatients 7 . Written inform consent obtain patient legally authorize representative 1 . Contraindication MRI 2 . Progressive unstable stroke 3 . Preexisting active major neurological disease 4 . Preexisting active ( e.g. , chronic medication ) major psychiatric disease , major depression , schizophrenia , bipolar disease , dementia 5 . A history significant alcohol drug abuse prior 3 year 6 . Advanced liver , kidney , cardiac , pulmonary disease 7 . A terminal medical diagnosis consistent survival &lt; 1 year 8 . Substantial decrease alertness time randomization , define score 2 NIH Stroke Scale 9 . Pregnancy lactate ; note negative pregnancy test require patient female reproductive year 10 . Any condition would represent contraindication Cerebrolysin , include allergy Cerebrolysin 11 . Current enrolment another therapeutic study stroke stroke recovery 12 . Total serum bilirubin &gt; 4 mg/dL , alkaline phosphatase &gt; 250 U/L , SGOT/AST &gt; 150 U/L , SGPT/ALT &gt; 150 U/L , creatinine &gt; 3.5 mg/dL ; cardiopulmonary deficit large enough interfere reasonable participation physiotherapy trial . 13 . Previous porcine brain peptide administration history</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>cerebrolysin , stroke , motor function</keyword>
</DOC>